AstraZeneca and Bristol Myers Squibb in Advanced Merger Talks

On August 3, reports confirmed that AstraZeneca and Bristol Myers Squibb (BMS) have been holding preliminary merger discussions for several months. A person familiar with the matter corroborated the Financial Times story that the talks could produce a combined market capitalisation of roughly $400 billion, creating the world’s fourth-largest pharmaceutical group by value and the largest by revenue.

AstraZeneca, Bristol Myers Squibb in Merger Talks to Create Nearly $400 Billion Pharma Giant

• AstraZeneca – led by CEO Pascal Soriot since 2012, the UK-based drugmaker is valued at about £196 billion ($264 billion) and completed a direct NYSE listing in February 2026.

CNBC

• BMS – headquartered in Princeton, New Jersey, is valued at roughly $133 billion and faces patent expirations for its cancer immunotherapy Opdivo and blood-thinner Eliquis by 2028.

BioSpace

• Combined valuation: ~ $400 billion.

AstraZeneca, Bristol Myers Squibb in Merger Talks to Create Nearly $400 Billion Pharma Giant

• Oncology revenue 2025: AstraZeneca $25 billion; BMS Opdivo $10 billion.

BioSpace

• Imfinzi revenue 2025: $6.06 billion.

AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing

• Q2 2026 revenue: BMS $12.97 billion (up 5 % YoY); AstraZeneca $15.3 billion (up 6 %).

AstraZeneca shares slump after $400bn BMS merger rumours

• Patent-cliff exposure: William Blair estimates $50 billion of 2025 revenue at risk by 2030.

BioSpace

• Growth target: AstraZeneca aims for $80 billion in annual sales by 2030.

$400 Billion Pharma “Merger of the Century”: AstraZeneca in Merger Talks with Bristol-Myers Squibb

• U.S. expansion: The merger would deepen AstraZeneca’s presence in its largest market.

il Sole 24 Ore

• Portfolio complementarity: BMS adds cardiovascular and hematology assets; AstraZeneca contributes a broad oncology suite, enabling combination regimens.

BioSpace

• Regulatory scrutiny: Overlapping immunotherapies (Opdivo vs. Imfinzi) are expected to trigger antitrust reviews in the United States, Europe and the United Kingdom.

BioSpace

• An AstraZeneca spokesperson declined to comment.

Reuters

• Bristol Myers Squibb did not immediately respond.

AstraZeneca-Bristol Talks Signal $400 Billion Pharma Patent-Cliff Merger

• Share-price impact: Reuters reported a 9 % drop in AstraZeneca’s London shares; Bloomberg cited 7 %, Business-Live 6 %. BMS shares rose modestly (6 % pre-market in Biospace, 3.8 % in Coinpaper).

AstraZeneca shares slump after $400bn BMS merger rumours

• Deal structure: Sources suggest a mix of cash and stock, but terms remain undisclosed.

AstraZeneca is negotiating a merger that would create a $400 billion pharmaceutical giant.

• Regulatory timeline: No concrete schedule for antitrust clearance or integration planning has been provided.

$400 Billion Pharma “Merger of the Century”: AstraZeneca in Merger Talks with Bristol-Myers Squibb